BioArctic AB

BIOA B

Equity

ISIN SE0010323311 / Valor 38514501

NASDAQ Nordic Exchange Stockholm, Equities (2025-11-21)

SEK 279.00-1.90%

BioArctic AB
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

BioArctic AB is a Swedish research-oriented biopharmaceutical company focused on developing new treatments for neurodegenerative disorders. With a diverse project portfolio at various stages of development, the company aims to improve the health of patients and create value for stakeholders. BioArctic's cutting-edge expertise in this area makes it an attractive partner for collaborations and investments in the biopharmaceutical industry.

Summarized from source with an LLMView SourceSector: Healthcare

Record Royalties

BioArctic AB achieved record royalties in Q2 2025, highlighting the increasing success and market penetration of its flagship product, Leqembi®.

EU Milestone

The company reached a significant EU milestone in the second quarter, further establishing its presence in the European market and paving the way for future growth opportunities.

Partnership with Novartis

BioArctic AB entered into a new partnership with Novartis, receiving an upfront payment of USD 30 million. This collaboration is expected to generate up to USD 772 million in additional milestone payments, along with tiered mid single-digit royalties on future global sales.

Summarized from source with an LLMView Source

Key figures

50.5%1Y

-5.93%3Y

199%5Y

Performance

66.1%1Y

60.0%3Y

76.3%5Y

Volatility